What does caliectasis (dilation of the calyces) and peliectasis (dilation of the renal pelvis) of the kidney mean?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Understanding Caliectasis and Peliectasis of the Kidney

Caliectasis (dilation of the calyces) and peliectasis (dilation of the renal pelvis) are descriptive terms for fluid-filled expansion of the kidney's collecting system, which modern guidelines now recommend replacing with the unified term "urinary tract dilation" (UTD) to standardize communication across specialties. 1

Modern Terminology and Classification

  • The 2014 multidisciplinary consensus from 8 professional societies established that terms like "hydronephrosis," "pelviectasis," "caliectasis," and "pelvicaliectasis" should be replaced with the standardized "urinary tract dilation" (UTD) classification system. 1

  • The UTD system provides objective grading based on multiple parameters including anteroposterior diameter (APD), central and peripheral calyceal dilation, parenchymal thickness and appearance, ureteral abnormalities, and bladder appearance. 1

  • Postnatal normative values established that APD <10 mm represents physiologic dilation that typically requires no intervention. 1, 2

Clinical Significance

When Dilation is Physiologic (Normal Variant)

  • Approximately 80% of mild urinary tract dilation detected prenatally resolves spontaneously and represents a normal physiologic variant. 2

  • APD <10 mm postnatally with no calyceal dilation, normal parenchymal thickness, and no ureteral abnormalities is considered normal. 1, 2

When Dilation is Pathologic

  • Pathologic dilation occurs when there is central or peripheral calyceal dilation, parenchymal thinning or abnormalities, ureteral dilation, or APD ≥10 mm postnatally. 2

  • Common pathologic causes include vesicoureteral reflux, ureteropelvic junction obstruction, multicystic dysplastic kidneys, and posterior urethral valves. 2

  • For obstructive lesions, APD ≥15 mm detected in the third trimester serves as a threshold predictive of ureteropelvic junction obstruction. 1

Diagnostic Approach

Prenatal Detection

  • Gestational age-dependent thresholds apply: APD <4 mm is normal before 28 weeks, and APD <7 mm is normal after 28 weeks gestation. 1, 2

  • UTD occurs in 1-2% of pregnancies, with most representing transient findings. 2

Postnatal Evaluation

  • Renal bladder ultrasound should be performed after 48 hours of life, as earlier studies underestimate dilation due to physiologic neonatal third spacing. 2

  • Complete resolution of third spacing occurs by day 7-10. 2

  • The Society for Fetal Urology (SFU) grading system remains the most commonly used postnatal classification, ranging from grade 1 (urine barely splits sinus) to grade 4 (parenchymal compromise). 1

Management Based on Severity

Low-Risk UTD (UTD A1/P1)

  • Follow-up ultrasound at ≥32 weeks gestation if detected prenatally, with postnatal follow-up to confirm resolution. 2

  • No prophylactic antibiotics or invasive testing typically required. 1

Moderate to Severe UTD (UTD A2-3/P2-3)

  • Serial ultrasound monitoring every 4 weeks prenatally is recommended. 2

  • Specialty consultation with pediatric urology and/or nephrology is indicated. 1, 2

  • Additional postnatal imaging including voiding cystourethrogram (VCUG) and functional imaging may be necessary. 1

Critical Pitfalls to Avoid

  • Do not perform ultrasound evaluation too early after birth (<48 hours), as this underestimates the degree of dilation. 2

  • Mild renal pelvic dilation (3-10 mm APD without caliectasis) is not predictive of vesicoureteral reflux and should not automatically trigger voiding cystourethrography. 3

  • Ultrasound has >90% sensitivity for hydronephrosis but cannot always determine the underlying cause with certainty. 1

  • False-negative ultrasound studies can occur with dehydration, early obstruction, or compression by tumors or fibrosis. 1

Prognostic Indicators

  • Combined assessment of APD and diffuse caliectasis better predicts need for surgical intervention than APD measurement alone. 4

  • APD ≥6-9 mm with diffuse caliectasis carries a hazard ratio of 19.5 for surgery versus 0.59 for APD ≥6-9 mm alone. 4

  • The SFU grading system demonstrates high positive predictive value for both kidney function and need for surgical intervention in ureteropelvic junction obstruction. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Congenital Pelvicalyceal System Dilation Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A New Grading System for the Management of Antenatal Hydronephrosis.

Clinical journal of the American Society of Nephrology : CJASN, 2015

Related Questions

What should be done for a 5-year-old child with a renal pelvis dilatation of 56mm on ultrasound (USG) scan, which has increased from 28mm 6 months ago?
What is the management plan for a 15-month-old male with a renal pelvis dilatation of 0.97 cm?
What is the management plan for a patient with a normal left kidney and an extrarenal pelvis?
What are the recent guidelines for managing renal pelvis dilation?
What is the preferred initial treatment between Vonoprazan (potassium-competitive acid blocker (P-CAB)) and pantoprazole (proton pump inhibitor (PPI)) for a patient with typical gastroesophageal reflux disease (GERD) or peptic ulcer disease (PUD) without significant impaired renal function?
What is the best course of action for an immunocompromised patient on dialysis and immunosuppressive therapy with significantly elevated C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR), joint pains, and low Complement 3 (C3) levels?
What is the optimal decision tree for managing chronic back pain in patients presenting to an orthopedic spine clinic, considering their unique medical history, lifestyle, and treatment goals?
When can Xarelto (rivaroxaban) be restarted after surgery in a patient with a history of deep vein thrombosis (DVT)?
Is it safe to leave Annovera (segesterone acetate and ethinyl estradiol) in for 1 year without breaks to manage heavy periods (menorrhagia)?
When do we administer vitamin K (phylloquinone) to a patient on warfarin (coumarin) with an elevated international normalized ratio (INR)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.